ClinicalTrials.gg
Not yet recruitingNCT07950007Updated Nov 20, 2026

ctDNA-Guided Neoadjuvant Therapy in HER2+ Breast Cancer

A Phase 2 interventional study of T-DXd and ctDNA Testing Blood Test in HER2 + Breast Cancer, sponsored by Jin Sun Bitar. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Jin Sun Bitar · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The convergence of evidence from neoCARHP (comparable pCR between TCHP and THP in an unselected population), DB-11 (activity of T-DXd-THP in high-risk HER2-positive early breast cancer), and I-SPY2 ctDNA data (early ctDNA clearance predicts favorable response and outcomes) provides a strong rationale for biomarker-guided treatment selection. This study uses early on-treatment ctDNA response after standardized THP induction to direct therapy intensity rather than reflexively escalating all patients.

Unlike non-biomarker-selected escalation approaches, this study uses ctDNA as a dynamic biomarker to tailor therapy: patients with early molecular clearance continue THP without carboplatin or ADC exposure, while patients with persistent molecular tumor burden escalate to T-DXd.

02

Conditions studied

  • HER2 + Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • docetaxel
  • trastuzumab
  • pertuzumab
  • T-DXd
  • ctDNA
03

In context

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's planned enrollment of 60 is below the median of 72 across 10,914 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

This is the only study on the registry with Jin Sun Bitar as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed, confirmed stage II-III -positive breast cancer (HER2-positive defined per ASCO/CAP guidelines: IHC 3+ or ISH-amplified)
  • No prior systemic therapy for breast cancer
  • Adequate tumor tissue available for molecular profiling and ctDNA assay design
  • Adequate peripheral blood samples obtainable for serial ctDNA testing
  • Age ≥ 18 years
  • performance status 0-2
  • Adequate organ function as defined by:

    • (ANC) ≥ 1,500/µL
    • ≥ 100,000/µL
    • ≥ 9.0 g/dL
    • Total ≤ 1.5 × (ULN)
    • /ALT ≤ 2.5 × ULN
    • ≥ 50 mL/min (Cockcroft-Gault)
    • (LVEF) ≥ 55% by echocardiogram or MUGA scan
  • Women of must have a negative pregnancy test and agree to use effective during treatment and for the protocol-specified period after the last dose of HER2-directed therapy/T-DXd, per applicable prescribing information and institutional standards.
  • Written obtained from subject and ability for subject to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Distant disease (Stage IV)
  • Prior invasive breast cancer within the past 5 years
  • Prior chemotherapy, radiation therapy, or targeted therapy for current breast cancer
  • Known to any component of the treatment regimen, including docetaxel, trastuzumab, pertuzumab, or T-DXd
  • Active cardiac disease including: congestive heart failure ( Class II or above), unstable angina, myocardial infarction within 6 months, uncontrolled hypertension, or arrhythmia
  • Pregnant or breastfeeding
  • History of, or current, interstitial lung disease/pneumonitis; active uncontrolled infection requiring systemic therapy
  • Any other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Single Arm

    Drug: T-DXd · Device: ctDNA Testing Blood Test

Interventions

  • DrugT-DXd

    All patients begin with THP for Cycles 1-4. ctDNA is assessed at baseline,C2D1, C5D1, and at the preoperative and postoperative time points. C2D1 ctDNA determines subsequent treatment: ctDNA-negative patients continue THP through C6, while ctDNA-positive patients escalate to T-DXd from C5 through C8 after 4 cycles of THP.

  • DevicectDNA Testing Blood Test

    A tumor-informed, personalized ctDNA assay will be used. Whole genome sequencing (WGS) will be performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue and matched-normal DNA from buffy coat to identify somatic variants. Based on the WGS results, multiplex PCR primers will be designed for 64 tumor-specific, somatic single-nucleotide variants for each patient. A sample will be considered ctDNA-positive if ≥2 of 64 variants are detected in the circulating cell-free DNA.

06

What researchers measure

Primary outcomes

  1. pCR rate in the HR-positive/HER2-positive group

    Pathologic complete response (pCR) is defined as the absence of residual invasive cancer in the breast and regional lymph nodes (ypT0/is ypN0) at the time of surgery following completion of neoadjuvant therapy.

    Time frame: Time of Surgery, up to 24 weeks post on study

  2. pCR rate in the HR-negative/HER2-positive group

    Pathologic complete response (pCR) is defined as the absence of residual invasive cancer in the breast and regional lymph nodes (ypT0/is ypN0) at the time of surgery following completion of neoadjuvant therapy.

    Time frame: Time of Surgery, up to 24 weeks post on study

Secondary outcomes

  1. ctDNA Clearance Rate

    Patients who achieve ctDNA clearance during and after neoadjuvant therapy

    Time frame: From enrollment to end of treatment at 8 cycles (24 weeks)

  2. Event-Free Survival (EFS)

    Time from Enrollment to disease progression precluding surgery, local or distant recurrence, or death from any cause

    Time frame: From time of enrollment until date of documented progression or date of death from any cause, whichever came first, assessed up to 67 months

  3. Residual Cancer Burden (RCB)

    Proportion of patients achieving RCB-0 or RCB-1 (minimal residual disease) at surgery based on molecular subtypes

    Time frame: Time of Surgery, up to 24 weeks post on study

  4. Adverse Events

    Time frame: From enrollment till Time of Surgery, up to 24 weeks post enrollment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Aug 2029, 30 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 30 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 20, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
Aug 1, 2029
CompletionEst.
Feb 1, 2034
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950007
Lead sponsor
Jin Sun Bitar
Collaborators
Natera, Inc.
Responsible party
Jin Sun Bitar (Sponsor-Investigator, Cedars-Sinai Medical Center) — Sponsor-investigator
First posted
Nov 20, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Aug 1, 2029 (estimated)
Completion
Feb 1, 2034 (estimated)
Last update
Nov 20, 2026

Study contacts

Clinical Trials Navigator
Contact
groupcancertrialinformation@cshs.org
310-423-2133

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion